Mereo Biopharma Overview

  • Founded

  • 2015

Founded
  • Status

  • Public

  • Employees

  • 36

Employees
  • Stock Symbol

  • MREO

Stock Symbol
  • Investments

  • 2

  • Share Price

  • $0.32

  • (As of Thursday Closing)

Mereo Biopharma General Information

Description

Developer of drugs and therapies catering to patients with rare diseases and cancer. The company is engaged in the development and commercialization of innovative therapeutics that aim to improve outcomes for people in both oncology and rare diseases.

Contact Information

Website
www.mereobiopharma.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Primary Office
  • 1 Cavendish place
  • London W1G 0QF
  • England, United Kingdom
+44 0333 000 0000

Mereo Biopharma Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mereo Biopharma Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.32 $0.31 $0.17 - $0.66 $121M 339M 66.07 -$1.54

Mereo Biopharma Financials Summary

In Thousands,
USD 		TTM 31-Dec-2022 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 89,058
Revenue 0 0 50,143 0
EBITDA (40,353) (40,353) 25,967 (203,142)
Net Income (42,145) (42,145) 17,499 (209,750)
Total Assets 106,592 106,592 170,617 85,786
Total Debt 15,458 15,458 22,620 24,444
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Mereo Biopharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Mereo Biopharma‘s full profile, request access.

Request a free trial

Mereo Biopharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of drugs and therapies catering to patients with rare diseases and cancer. The company is engaged in the devel
Drug Discovery
London, United Kingdom
36 As of 2022
00000
000000000 00000

00000

uip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate
0000000000000
Thousand Oaks, CA
00000 As of 0000
00.000
000000000000 00.000

0000 0

si ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in
0000000000000
Macclesfield, United Kingdom
00 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mereo Biopharma Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Amgen Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
0000 000000 Formerly VC-backed Macclesfield, United Kingdom 00 000.00 000000000 000.00
000000 Venture Capital-Backed Oxford, United Kingdom 00 000.00 0000000000 0 000.00
000000 Formerly VC-backed Bothell, WA 0000 00.000 000000&0 00.000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 11 competitors. Get the full list »

Mereo Biopharma Patents

  • 105

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 8

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Mereo Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2017368155-A1 Methods for treatment of cancer comprising tigit-binding agents Active 30-Nov-2016 000000000
CA-3044664-A1 Methods for treatment of cancer comprising tigit-binding agents Active 30-Nov-2016 000000000
EP-3548071-A1 Methods for treatment of cancer comprising tigit-binding agents Pending 30-Nov-2016 000000000
US-20190284269-A1 Methods for treatment of cancer comprising tigit-binding agents Active 30-Nov-2016 000000000
CA-3044664-C Methods for treatment of cancer comprising tigit-binding agents Active 30-Nov-2016 C07K14/47
To view Mereo Biopharma’s complete patent history, request access »

Mereo Biopharma Executive Team (11)

Name Title Board Seat Contact Info
Christine Fox Chief Financial Officer
John Lewicki Ph.D Chief Scientific Officer
Wills Hughes-Wilson Chief Patient Access and Commercial Planning
John Richard Ph.D Co-Founder & Chief Business Officer
Charles Sermon General Counsel, Legal & Secretary, Administration
You’re viewing 5 of 11 executive team members. Get the full list »

Mereo Biopharma Board Members (12)

Name Representing Role Since
Anders Ekblom Ph.D Mereo Biopharma Board Member 000 0000
Deepika Pakianathan Ph.D Self Board Member 000 0000
Jeremy Bender Ph.D Self Board Member 000 0000
Michael Wyzga Self Chairman & Board Member 000 0000
Pierre Jacquet Ph.D Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Mereo Biopharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mereo Biopharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Mereo Biopharma‘s full profile, request access.

Request a free trial

Mereo Biopharma Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 23-Apr-2019 0000000000 000.00 Drug Discovery 000000 00
Novartis (Mid-Stage Clinical Product Portfolio) 29-Jul-2015 Corporate Asset Purchase Buildings and Property 000000 00
To view Mereo Biopharma’s complete investments and acquisitions history, request access »

Mereo Biopharma Subsidiaries (1)

Company Name Industry Location Founded
0000000 0000000000 Drug Discovery Redwood City, CA 0000
To view Mereo Biopharma’s complete subsidiaries history, request access »

Mereo Biopharma ESG

Risk Overview

Risk Rating

Updated March, 26, 2020

31.84 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 9,433

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 709

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 262

Rank

00.00

Percentile

To view Mereo Biopharma’s complete esg history, request access »